icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
rExv50ZUr4k9mAcv
Listen
